BrightView Holdings, Inc., through its subsidiaries, provides commercial landscaping services in the United States. It operates in two segments, Maintenance Services and Development Services. The Maintenance Services segment delivers a suite of recurring commercial landscaping services, including mowing, gardening, mulching and snow removal, water management, irrigation maintenance, tree care, golf course maintenance, and specialty turf maintenance. Its customers' properties include corporate and commercial properties, homeowners associations, public parks, hotels and resorts, airport authorities, municipalities, hospitals and other healthcare facilities, educational institutions, restaurants and retail, and golf courses. This segment's customer base includes approximately 11,700 office parks and corporate campuses 10,000 residential communities, and 700 educational institutions. The Development Services segment offers landscape architecture and development services for new facilities and redesign projects. Its services include project design and management services, landscape architecture and installation, irrigation installation, tree moving and installation, pool and water features, sports field, and other services. BrightView Holdings, Inc. also operates as official field consultant to Major League Baseball. The company was formerly known as BrightView Acquisition Holdings, Inc. BrightView Holdings, Inc. was founded in 1939 and is headquartered in Blue Bell, Pennsylvania.

BrightView Holdings Inc.

Brightview Holdings ( ($BV) ) has released its Q4 earnings. Here is a breakdown of the information Brightview Holdings presented to its investors. ...

BrightView Holdings Reports Record EBITDA Amid Revenue Dip

Bouvet ASA ( ($DE:BV4) ) has issued an announcement. Bouvet ASA has announced the implementation of its regular share purchase program, where prima...

Bouvet ASA Implements Share Purchase Program with Insider Participation

Bouvet ASA ( ($DE:BV4) ) has issued an update. Bouvet ASA has announced the implementation of its employee share purchase program, allowing 1,856 e...

Bouvet ASA Launches Employee Share Purchase Program

The latest announcement is out from Advanced Braking Technology Limited ( ($AU:ABV) ). Advanced Braking Technology Limited announced that all resol...

Advanced Braking Technology Passes All Resolutions at 2025 AGM

Advanced Braking Technology Limited ( ($AU:ABV) ) has provided an announcement. Advanced Braking Technology Ltd (ABT) reported strong growth and so...

Advanced Braking Technology Reports Strong FY25 Growth and Strategic Expansion

In a report released today, Inigo Vega from Jefferies maintained a Buy rating on Banco Bilbao Vizcaya Argentaria, with a price target of €21.00. Ve...

Banco Bilbao Vizcaya Argentaria (BVA) Gets a Buy from Jefferies

There’s a lot to be optimistic about in the Industrial Goods sector as 2 analysts just weighed in on BrightView Holdings (BV – Research Report) and...

Analysts’ Top Industrial Goods Picks: BrightView Holdings (BV), Brady (BRC)

In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on AbbVie, with a price target of $222.00. The compan...

AbbVie (ABBV) Gets a Buy from Evercore ISI

Banco Bilbao ( ($BBVA) ) has issued an update. On November 17, 2025, BBVA announced the execution of a buyback program for its own shares, which to...

BBVA Executes Significant Share Buyback Program in November 2025

In a report released today, Trion Reid from Berenberg Bank maintained a Buy rating on Borussia Dortmund GmbH & Co. KGaA, with a price target of €5....

Borussia Dortmund GmbH & Co. KGaA (0DVE) Receives a Buy from Berenberg Bank

Bavarian Nordic A/S (($BVNRY)) has held its Q3 earnings call. Read on for the main highlights of the call. Bavarian Nordic’s recent earnings call c...

Bavarian Nordic’s Earnings Call: Strong Growth Amid Challenges

In a report released on November 13, Thomas Renaud from Kepler Capital maintained a Buy rating on Claranova SA, with a price target of €3.40. The c...

Claranova SA (0N6K) Receives a Buy from Kepler Capital

The latest update is out from BioVaxys Technology ( ($TSE:BIOV) ). BioVaxys Technology Corp. has announced a debt settlement transaction with certa...

BioVaxys Announces Debt Settlement to Strengthen Financial Position

DBS analyst Zheng Feng Chee maintained a Buy rating on Thai Beverage Public Co today and set a price target of S$0.63. According to TipRanks, Feng ...

DBS Sticks to Its Buy Rating for Thai Beverage Public Co (TBVPF)

In a report released today, Sam Teeger from Citi maintained a Buy rating on Breville Group , with a price target of A$36.03. Teeger covers the Cons...

Citi Keeps Their Buy Rating on Breville Group  (BVILF)

An announcement from Bouvet ASA ( ($DE:BV4) ) is now available. Bouvet ASA has announced an additional dividend of NOK 0.70 per share, with shares ...

Bouvet ASA Announces Additional Dividend for 2024

The latest announcement is out from BioVaxys Technology ( ($TSE:BIOV) ). BioVaxys Technology Corp. announced an extension of its non-brokered priva...

BioVaxys Extends Private Placement to Boost Immunotherapy Pipeline

Itau Unibanco ( ($ITUB) ) just unveiled an announcement. On November 11, 2025, Itaú Unibanco announced its decision to repurchase all of its Tier 2...

Itaú Unibanco to Repurchase R$3.6 Billion in Tier 2 Financial Bills

Citi analyst Sam Teeger maintained a Buy rating on Breville Group today and set a price target of A$36.03. According to TipRanks, Teeger is a 3-sta...

Breville Group  (BVILF) Gets a Buy from Citi

Itau Unibanco ( ($ITUB) ) just unveiled an announcement. On November 4, 2025, Itaú Unibanco released its condensed financial statements for the fir...

Itaú Unibanco Reports Strong Financial Performance and Innovations in November 2025

Itau Unibanco ( ($ITUB) ) has issued an announcement. On November 4, 2025, Itaú Unibanco released its updated financial projections for the fiscal ...

Itaú Unibanco Updates 2025 Financial Projections Amid Market Conditions

Itau Unibanco ( ($ITUB) ) has issued an update. On November 4, 2025, Itaú Unibanco released its Management Discussion & Analysis and Condensed Fina...

Itaú Unibanco Reports Strong Q3 2025 Financial Performance

Itau Unibanco ( ($ITUB) ) has shared an announcement. On November 4, 2025, Itaú Unibanco released its financial results for the third quarter of 20...

Itaú Unibanco Reports Strong Q3 2025 Financial Results

Itau Unibanco ( ($ITUB) ) has provided an announcement. On November 4, 2025, Itaú Unibanco announced a revised projection for the year 2025, highli...

Itaú Unibanco Releases Revised 2025 Projections

The latest announcement is out from Itau Unibanco ( ($ITUB) ). On November 4, 2025, Itaú Unibanco’s Board of Directors convened to review the finan...

Itaú Unibanco Approves Financial Statements for Q1-Q3 2025

Diamond Hill Investment Group ( ($DHIL) ) just unveiled an announcement. As of October 31, 2025, Diamond Hill Capital Management reported assets un...

Diamond Hill Reports $30.02 Billion in Assets

The latest announcement is out from Cobra Venture ( ($TSE:CBV) ). Cobra Venture Corporation is negotiating a reverse takeover with Robinson Energy ...

Cobra Venture and Robinson Energy Progress in Reverse Takeover Deal

Barclays analyst Benjamin Theurer maintained a Buy rating on Arca Continental SAB de C V yesterday and set a price target of peso230.00. The compan...

Arca Continental SAB de C V (EMBVF) Gets a Buy from Barclays

Compania de Minas Buenaventura SAA (($BVN)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call of...

Buenaventura’s Mixed Q3 2025 Earnings Call Highlights

With the S&P 500 ($SPX) up 22.8% over the past six months and the Nasdaq ($NDX) surging an even stronger 36.0%, there’s no denying that equities ar...

How MRK, ABBV, and BMY Could Rescue Investor Portfolios in a Downturn

Analysts have been eager to weigh in on the Healthcare sector with new ratings on AbbVie (ABBV – Research Report) and Merus (MRUS – Research Report...

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Merus (MRUS)

The latest announcement is out from Bellavista Resources Ltd ( ($AU:BVR) ). Bellavista Resources Limited, a company listed on the Australian Securi...

Bellavista Resources Postpones AGM to Facilitate Shareholder Engagement

Kepler Capital analyst Thomas Renaud maintained a Buy rating on Claranova SA on October 30 and set a price target of €3.40. The company’s shares cl...

Kepler Capital  Sticks to Their Buy Rating for Claranova SA (0N6K)

AbbVie’s ($ABBV) shares weakened on Friday, despite the American drugmaker’s third-quarter fiscal year 2025 earnings surpassing Wall Street’s expec...

AbbVie Stock (ABBV) Wobbles as Humira Sales Take a Hit, Dims Q3 Glow

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AbbVie, with a price target of $280.00. The company’s shares opene...

TD Cowen Remains a Buy on AbbVie (ABBV)

In a report released on October 29, Justine Telliez from Kepler Capital maintained a Buy rating on DBV Technologies, with a price target of €6.00. ...

Kepler Capital  Reaffirms Their Buy Rating on DBV Technologies (0QAJ)

Itau Unibanco ( ($ITUB) ) has shared an update. On October 30, 2025, Itaú Unibanco Holding S.A. held a Board of Directors meeting where significant...

Itaú Unibanco Announces Executive Changes at Board Meeting

The latest announcement is out from BioVaxys Technology ( ($TSE:BIOV) ). BioVaxys Technology Corp. has announced an increase in its non-brokered pr...

BioVaxys Upsizes Private Placement to Boost Immunotherapy Pipeline

Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie is currently conducting a Phase 1 clinical study titled ‘A Phase 1, Do...

AbbVie’s New Phase 1 Study: A Potential Game Changer?

In a report released today, Benjamin Toms from RBC Capital maintained a Buy rating on Banco Bilbao Vizcaya Argentaria, with a price target of €17.5...

RBC Capital Sticks to Their Buy Rating for Banco Bilbao Vizcaya Argentaria (BVA)

Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently updated its clinical study titled A Phase 2, Multicenter, Ran...

AbbVie’s HIV Treatment Study Update: Key Insights for Investors

In a report released today, Sam Teeger from Citi maintained a Hold rating on Breville Group , with a price target of A$36.03. The company’s shares ...

Citi Keeps Their Hold Rating on Breville Group  (BVILF)

The latest update is out from BioVaxys Technology ( ($TSE:BIOV) ). BioVaxys Technology Corp. announced the conversion of $125,000 in unsecured conv...

BioVaxys Converts Debentures into Equity, Strengthening Financial Position

In a report released today, Arthur Truslove from Citi maintained a Hold rating on Bureau Veritas, with a price target of €29.75. The company’s shar...

Bureau Veritas (0MH1) Gets a Hold from Citi

Jefferies analyst Keith Devas maintained a Hold rating on Prestige Consumer Healthcare today and set a price target of $71.00. The company’s shares...

Jefferies Remains a Hold on Prestige Consumer Healthcare (PBH)

The latest announcement is out from Bioventix ( ($GB:BVXP) ). Bioventix plc announced that Bruce Hiscock, the Chief Financial Officer, purchased 11...

Bioventix CFO Increases Stake with Share Purchase

DBS analyst Zheng Feng Chee maintained a Buy rating on Thai Beverage Public Co today and set a price target of S$0.63. The company’s shares closed ...

Thai Beverage Public Co (TBVPF) Receives a Buy from DBS

In a report released on October 24, Elias New from Kepler Capital maintained a Hold rating on Cargotec, with a price target of €45.00. The company’...

Cargotec (CYJBF) Receives a Hold from Kepler Capital

The latest announcement is out from Bravada Gold ( ($TSE:BVA) ). Bravada Gold Corporation has filed a technical report updating the in-pit gold and...

Bravada Gold Extends Wind Mountain Project’s Resource and Mine Life

Abbvie (($ABBV)) announced an update on their ongoing clinical study. Study Overview: AbbVie is conducting a multicenter, open-label study titled ‘...

AbbVie’s ABBV-932 Study: A New Hope for Bipolar Disorder Treatment?

Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie has completed a Phase 3 clinical study titled ‘A Phase 3 Randomized, P...

Current Quarter	$0.29	Next Quarter	$0.03
Current Year	$0.71	Next Year	$0.76
QoQ Growth	-89.7%	YoY Growth	+7.0%
3Y EPS CAGR	-21.9%	Target Price	$17.93
Consensus	Buy	Upside	+47.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BV	$12.18	+3.75%	1.85M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BV	$12.18	+3.7%	1.85M
3
4
5
6

BV

BV

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get BrightView Holdings Inc. Data in Excel

Get BrightView Holdings Inc. Data in Excel